questionText: To ask the Secretary of State for Health and Social Care, what steps the Government is taking through the UK Life Sciences Industrial Strategy to prevent incentives or regulatory reforms from enabling large pharmaceutical companies to increase medicine prices; and whether the Government will publish an impact assessment of how current industry pricing behaviours influence NHS drug costs and UK supply-chain resilience.
answerText: The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) controls the cost of sales of branded medicines to the National Health Service. The VPAG has a variable headline payment percentage, which accounts for changes to the cost of med...
heading: Drugs: Prices